Home
>
US Stocks
>
COGENT BIOSCIENCES INC

COGENT BIOSCIENCES INC (COGT)

$11.23

+0.03

(+0.27%)▲

Market is closed - opens 7 PM, 30 May 2023

Performance

  • $11.13
    $11.30
    $11.23
    downward going graph

    0.89%

    Downside

    Day's Volatility :1.5%

    Upside

    0.62%

    downward going graph
  • $4.13
    $18.07
    $11.23
    downward going graph

    63.22%

    Downside

    52 Weeks Volatility :77.14%

    Upside

    37.85%

    downward going graph

Returns

PeriodCOGENT BIOSCIENCES INCSector (Health Care)Index (Russel 2000)
3 Months
-15.12%
0.3%
-6.7%
6 Months
-10.73%
-8.3%
-6.2%
1 Year
143.6%
-4.8%
-6.3%
3 Years
1909.3%
23.8%
26.9%

Highlights

Market Capitalization
796.7M
Book Value
$2.27
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.19
Wall Street Target Price
22.33
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-42.46%
Return On Equity TTM
-72.04%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
-121.6M
EBITDA
-158.4M
Diluted Eps TTM
-2.19
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.17
EPS Estimate Next Year
-2.12
EPS Estimate Current Quarter
-0.57
EPS Estimate Next Quarter
-0.59

Analyst Recommendation

Buy
    93%Buy
    6%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for COGENT BIOSCIENCES INC(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
13
12
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 98.84%

Current $11.23
Target $22.33

Technicals Summary

Sell

Neutral

Buy

COGENT BIOSCIENCES INC is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
COGENT BIOSCIENCES INC
COGENT BIOSCIENCES INC
0.09%
-10.73%
143.6%
1909.3%
-1.92%
Moderna, Inc.
Moderna, Inc.
-5.37%
-28.24%
-13.14%
103.02%
578.71%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-10.12%
-3.55%
9.07%
20.95%
140.97%
Seagen, Inc.
Seagen, Inc.
-2.85%
59.4%
42.61%
21.68%
240.77%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.35%
4.3%
22.83%
15.12%
110.67%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
COGENT BIOSCIENCES INC
COGENT BIOSCIENCES INC
NA
NA
NA
-2.17
-0.72
-0.42
0.0
2.27
Moderna, Inc.
Moderna, Inc.
11.22
11.22
0.0
-1.83
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.72
19.72
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.53
26.53
0.41
13.64
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
COGENT BIOSCIENCES INC
COGENT BIOSCIENCES INC
Buy
$796.7M
-1.92%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$48.1B
578.71%
11.22
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$79.5B
140.97%
19.72
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.3B
240.77%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$85.0B
110.67%
26.53
35.4%

Institutional Holdings

  • RA Capital Management, LLC

    8.46%

  • BlackRock Inc

    6.97%

  • COMMODORE CAPITAL LP

    6.73%

  • VR Adviser, LLC

    5.69%

  • TCG Crossover Management, LLC

    5.12%

  • Vanguard Group Inc

    4.98%

Corporate Announcements

  • COGENT BIOSCIENCES INC Earnings

    COGENT BIOSCIENCES INC’s price-to-earnings ratio stands at None

    Read More

Company Information

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Cogent Biosciences is headquartered in Cambridge, MA.

Organization
COGENT BIOSCIENCES INC
Employees
138
CEO
Mr. Andrew R. Robbins M.B.A.
Industry
Health Technology

Discover More

FAQs